Systemic therapy for psoriasis and the risk of herpes zoster: A 500000 person-year study

JAMA Dermatology

Volumn 151, Issue 5, 2015, Pages 533-538

  Shalom, Guy ^a,b,c   Zisman, Devy ^d,e   Bitterman, Haim ^a,c,e   Harman Boehm, Ilana ^a,b   Greenberg Dotan, Sari ^c   Dreiher, Jacob ^b,c   Feldhamer, Ilan ^c   Moser, Hadas ^b   Hammerman, Ariel ^c   Cohen, Yoram ^b   Cohen, Arnon D ^b,c  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c CLALIT HEALTH SERVICES   (Israel)

^d CARMEL MEDICAL CENTER   (Israel)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; BIOLOGICAL PRODUCT; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; PSORALEN; USTEKINUMAB; ACIVICIN; BIOLOGICAL FACTOR; DERMATOLOGICAL AGENT; ISOXAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; VARICELLA ZOSTER VACCINE;

ADULT; AGE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMMUNITY CARE; CONFERENCE PAPER; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENDER; HEALTH CARE FACILITY; HEALTH CARE ORGANIZATION; HERPES ZOSTER; HOSPITAL CARE; HUMAN; INCIDENCE; INFECTION RISK; ISRAEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTPATIENT CARE; PHOTOTHERAPY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSORIASIS; REGRESSION ANALYSIS; RISK REDUCTION; SOCIAL STATUS; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VARICELLA ZOSTER VIRUS; ADVERSE EFFECTS; COMORBIDITY; DRUG COMBINATION; EPIDEMIOLOGY; RISK FACTOR; SEX RATIO;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL FACTORS; CAUSALITY; COHORT STUDIES; COMORBIDITY; CYCLOSPORINE; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; INCIDENCE; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOTOTHERAPY; PSORIASIS; RISK FACTORS; SEX DISTRIBUTION;

EID: 84929677083     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.4956     Document Type: Conference Paper

References (26)

1. Schmader KE, Sloane R, Pieper C, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain. 2007;23(6):490-496.
2. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341-1349.
3. Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13:170.
4. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30.
5. Gnann JW Jr, Whitley RJ. Clinical practice: herpes zoster. N Engl J Med. 2002;347(5):340-346.
6. McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis. 2009;48(10):1364-1371.
7. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52(11):3403-3412.
8. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford). 2006;45(11):1370-1375.
9. Pérez-Sola MJ, Torre-Cisneros J, Pérez-Zafrilla B, Carmona L, Descalzo MA, Gómez-Reino JJ; BIOBADASER Study Group. Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. Med Clin (Barc). 2011;137(12):533-540.
10. Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol. 2010;6(3):165-174.
11. Galloway JB, Mercer LK, Moseley A, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2013;72(2):229-234.
12. Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007;57(8):1431-1438.
13. Serac G, Tubach F, Mariette X, et al. Risk of herpes zoster in patients receiving anti-TNF-a in the prospective French RATIO registry. J Invest Dermatol. 2012;132(3, pt 1):726-729.
14. Failla V, Jacques J, Castronovo C, Nikkels AF. Herpes zoster in patients treated with biologicals. Dermatology. 2012;224(3):251-256.
15. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301(7):737-744.
16. Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309(9):887-895.
17. Dreiher J, Kresch FS, Comaneshter D, Cohen AD. Risk of herpes zoster in patients with psoriasis treated with biologic drugs. J Eur Acad Dermatol Venereol. 2012;26(9):1127-1132.
18. Salvarani C, Cantini F, Olivieri I, et al. Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum. 2003;49(4):541-545.
19. Wendling D, Streit G, Toussirot E, Prati C. Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease. Joint Bone Spine. 2008;75(5):540-543.
20. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4(12):1483-1490.
21. Schmajuk G, Trivedi AN, Solomon DH, et al. Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA. 2011;305(5):480-486.
22. Whitley RJ, Gnann JW Jr. Herpes zoster in the age of focused immunosuppressive therapy. JAMA. 2009;301(7):774-775.
23. Langley RG, Carey WP, Rafal ES, et al. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther. 2005;27(9):1317-1328.
24. Antoniou C, Stefanaki I, Stratigos A, et al. The Greek experience with efalizumab in psoriasis from a university dermatologic hospital. Br J Dermatol. 2007;156(suppl 2):12-16.
25. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004;4(1):26-33.
26. Nordgaard-Lassen I, Dahlerup JF, Belard E, et al; Danish Society for Gastroenterology. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J. 2012;59(7):C4480.